Immunodeficiency, X-Linked, with Magnesium Defect, Epstein-Barr Virus Infection, and NeoplasiaD81.8

Last updated on: 01.06.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Immunodeficiency X-linked with magnesium defect, Epstein-Barr virus infection, and neoplasia, also known by the acronym XMEN, is a recessive X-linked immunodeficiency, a multisystem disorder, with congenital disruption of glycosylation characterized by CD4 (186940) lymphopenia, severe chronic viral infections, and impaired T lymphocyte activation. The disease is caused by loss-of-function mutations in the magnesium transporter 1 gene(MAGT1 gene). Affected individuals have a chronic infection with Epstein-Barr virus(EBV) and are susceptible to the development of EBV-associated lymphoproliferative B-cell disorders.

EtiopathogenesisThis section has been translated automatically.

MAGT1 functions as a non-catalytic subunit of the oligosaccharyltransferase complex and facilitates asparagine (N)-linked glycosylation of specific substrates. This results in XMEN congenital glycosylation disorder and combined immunodeficiency with EBV susceptibility.

The clinical phenotype is differentially expressed. Impaired glycosylation of key MAGT1-dependent glycoproteins and Mg2+ abnormalities explain some of the clinical immunodeficiencies.

Matsuda-Lennikov M et al (2019) demonstrated that EBV susceptibility in XMEN is associated with defective expression of the natural killer group 2 antiviral protein, member D (NKG2D), and abnormal Mg2+ transport. Poor glycosylation of NKG2D results in loss of function. Matsuda-Lennikov M et al (2019) found that MAGT1-dependent glycosylation is sensitive to Mg2+ content and that decreased Mg2+ impairs immune cell function through loss of specific glycoproteins. The receptor is decreased on CD8+ T cells and natural killer (NK) cells in this disease. It is the best biomarker for the disease. EBV-associated lymphoma is the major cause of severe morbidity in this immune disorder.

TherapyThis section has been translated automatically.

Treatment options to address the underlying disease mechanisms remain limited. Mg2+ supplementation is controversially discussed.

Note(s)This section has been translated automatically.

Disorders of magnesium homeostasis, often associated with altered magnesium channel expression and/or function, have been linked to a variety of diseases. Identification of genetic alterations and their functional consequences in patients with immunodeficiency has shown that magnesium and MAGT1 are key molecular determinants of T cell-mediated immune responses (Trapani Vet al. 2015)

Case report(s)This section has been translated automatically.

Li et al (2011) studied two brothers aged 7 and 3 years with recurrent infections, including chronic Epstein-Barr virus infections, and low CD4 T-cell counts. Both patients had an inverted CD4:CD8 ratio and fewer CD31 (PECAM1; 173445)-positive cells in the naive CD4-positive T-cell population, suggesting decreased thymic production. However, both patients had pronounced defects in T-cell receptor (TCR; see 186880)-mediated activation events and impaired early TCR signaling events such as NF-kappa-B (see 164011) and NFAT (see 600490) nuclear translocation. Patients did not show defects in B cell stimulation by B cell receptors or Toll-like receptors (reviewed in 603030). Li et al (2011) identified another patient with a similar phenotype who had died of chronic Epstein-Barr virus-associated lymphoma 5 years earlier at age 45. This one also had a similar T-cell defect in NF-kappa B and NFAT nuclear translocation in response to TCR stimulation, but not in response to downstream T-cell activation inducers.

Li et al (2014) reported 4 other unrelated patients, aged 4 to 23 years, with XMEN. All patients had chronic EBV infection with persistent EBV detectable in the blood. Other features included splenomegaly and variable recurrent infections, mainly respiratory. Three patients developed EBV-associated B-cell lymphoproliferative disorders, including the 23-year-old patient who died after hematopoietic stem cell transplantation. One patient had autoimmune cytopenia.

LiteratureThis section has been translated automatically.

  1. Blommaert E et al. (2019) Mutations in MAGT1 lead to a glycosylation disorder with a variable phenotype. Proc Natl Acad Sci U S A 116: 9865-9870.
  2. Li FY et al (2011) Second messenger role for Mg(2+) revealed by human T-cell immunodeficiency. Nature 475: 471-476.
  3. Li FY et al. (2014) XMEN disease: a new primary immunodeficiency affecting Mg(2+) regulation of immunity against Epstein-Barr virus. Blood 123: 2148-2152.
  4. Matsuda-Lennikov M et al (2019) Magnesium transporter 1 (MAGT1) deficiency causes selective defects in N-linked glycosylation and expression of immune-response genes. J Biol Chem 294:13638-13656.
  5. Ravell JC et al (2020) An Update on XMEN Disease. J Clin Immunol 40: 671-681.
  6. Trapani Vet al (2015) The role of MAGT1 in genetic syndromes. Magnes Res 28: 46-55.

Last updated on: 01.06.2022